Impact of thiazolidinedione safety warnings on medication use patterns and glycemic control among veterans with diabetes mellitus

Journal of Diabetes and its Complications

Volumn 25, Issue 3, 2011, Pages 143-150

  Shi, Lizheng ^a,b,c   Zhao, Yingnan ^a,c   Szymanski, Keith ^d   Yau, Lillian ^a,c   Fonseca, Vivian ^b,c  

^a TULANE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Southeast Louisiana Veterans Health Care System   (United States)

^d Takeda Pharmaceuticals America   (United States)

Author keywords

Diabetes mellitus; Glycemic control; Thiazolidinedione

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; GLIBENCLAMIDE; GLIBENCLAMIDE PLUS METFORMIN; GLIPIZIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DATA BASE; DIABETES MELLITUS; DRUG SAFETY; DRUG UTILIZATION; DYSLIPIDEMIA; FEMALE; GLYCEMIC CONTROL; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; VETERAN;

ADOLESCENT; ADULT; AGED; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DRUG LABELING; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; HYPERGLYCEMIA; MALE; MIDDLE AGED; RISK FACTORS; THIAZOLIDINEDIONES; UNITED STATES; VETERANS; YOUNG ADULT;

EID: 79955067911     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2010.06.003     Document Type: Article

References (19)

1. American Diabetes Association Standards of medical care in diabetes-2008 [see comment] Diabetes Care 31 Suppl 1 2008 S12 S54
2. Anonymous U.S. Food and Drug Administration Center for Drug Evaluation and Research. Summary minutes of the joint meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee 2007
3. Deeg M.A., and J.B. Buse Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia Diabetes Care 30 10 2007 2458 2464 (Pubitemid 47547772)
4. Dormandy J.A., B. Charbonnel, and D.J. Eckland Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone clinical trial in macroVascular events): a randomised controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)
5. FDA Information for healthcare professionals. Rosiglitazone maleate (marketed as Avandia, Avandamet, and Avandaryl) http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm143406.htm 2007
6. FDA News Manufacturers of some diabetes drugs to strengthen warning on heart failure risk 2007 www.fda.gov/bbs/topics/NEWS/2007/NEW01683.html
7. FDA News FDA issues safety alert on Avandia 2009 www.fda.gov/bbs/topics/ NEWS/2007/NEW01636.html
8. Fonseca, V. A. (2007). Rationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitus.
9. Ford E.S., and C. Li Trends in A1C concentrations among U.S. adults with diagnosed diabetes from 1999 to 2004. Diabetes Care 31 1 2008 102 104
10. Grundy S.M., and Brewer H.B. Jr National Heart, Lung, and Blood Institute: definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition Circulation 109 3 2004 433 438 (Pubitemid 38133916)
11. Home P.D., and S.J. Pocock Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial Lancet 373 9681 2009 2125 2135
12. Kahn S.E., and S.M. Haffner Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy New England Journal of Medicine 355 23 2006 2427 2443 (Pubitemid 44903747)
13. Nathan D.M., and Buse J.B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: update regarding thiazolidinediones: a consensus statement from the American Diabetes association and the European Association for the Study of Diabetes Diabetes Care 31 2008 173 175
14. Nathan D.M., and J.B. Buse Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 1 2009 193 203
15. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes New England Journal of Medicine 356 24 2007 2457
16. O'Connor P.J., and Rush W.A. Identifying diabetes mellitus or heart disease among health maintenance organization members: sensitivity, specificity, predictive value, and cost of survey and database method American Journal of Managed Care 4 1998 335 342 (Pubitemid 28350791)
17. Shah B.R., and D.N. Juurlink New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm Diabetic Medicine 25 7 2008 871 874
18. Starner C.I., and J.A. Schafer Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events Journal of Managed Care Pharmacy 14 6 2008 523 531
19. Zhu S.K., and Wang Z.M. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds American Journal of Clinical Nutrition 76 4 2002 743 749